P53, RB AND BCL-2 EXPRESSION DURING THE CELL-CYCLE - A STUDY IN PHYTOHEMAGGLUTININ-STIMULATED LYMPHOCYTES AND MICROWAVE IRRADIATED LYMPHOID-TISSUE SECTIONS
Ms. Mateo et al., P53, RB AND BCL-2 EXPRESSION DURING THE CELL-CYCLE - A STUDY IN PHYTOHEMAGGLUTININ-STIMULATED LYMPHOCYTES AND MICROWAVE IRRADIATED LYMPHOID-TISSUE SECTIONS, Journal of Clinical Pathology, 48(2), 1995, pp. 151-159
Aims-To determine the expression of p53, Rb, and bcl-2 during the cell
cycle in stimulated peripheral blood lymphocytes (PBLs) and microwave
heated reactive lymphoid tissue sections. Methods-The expression of p
53, Rb and bcl-2 proteins in paraffin wax embedded tonsil tissue secti
ons was detected by immunohistochemistry using an (APAAP) technique fo
llowing microwave irradiation. Flow cytometric analysis as performed o
n phytohaemagglutinin (PHA) stimulated PBLs, with simultaneous S fract
ion determination. Results-Expression of p53 protein was detected in r
eactive tonsil germinal centre cells, in some suprabasal cells in the
surface and cryptic epithelium, and in some endothelial cells. Analysi
s of p53 in PHA stimulated PBLs revealed expression of p53 by non-tumo
ral activated lymphocytes. Rb protein expression was increased in PHA
stimulated PBLs and was usually detected in most germinal centre B cel
ls, in isolated paracortical cells, in a fraction of endothelial cells
, and in most epithelial suprabasal cells. Expression of bcl-2 in stim
ulated lymphocytes was inversely correlated with proliferation, This c
onfirms findings in reactive tonsil tissue samples, where proliferatin
g cells located in the germinal centres and paracortical area are most
ly bcl-2 negative. Conclusions-Expression of these three oncogenic and
tumour suppressor proteins varies during the cell cycle in non-tumora
l cells. Consequently, tumoral growth fraction must be taken into acco
unt when analysing dysregulation of these three genes in lymphomas and
other tumours. The p53 protein may be detected in benign conditions,
as its expression is not synonymous with malignancy or mutation of the
p53 gene.